Open AccessCOMPREHENSIVE EVALUATION OF EXPRESSION PLATFORM: CHERRY PICKING THE ‘RIGHT’ TO ACCOMPLISH THE ‘BEST
Author(s) -
Shailendra Nath Gaur,
Kinjal Bhadresha,
Baldev Patel,
Meenu Saraf,
Rakesh Rawal
Publication year - 2020
Publication title -
towards excellence
Language(s) - English
Resource type - Journals
ISSN - 0974-035X
DOI - 10.37867/te120516
Subject(s) - monoclonal antibody , computational biology , biosimilar , computer science , chinese hamster ovary cell , biology , cell culture , microbiology and biotechnology , genetics , antibody
Mounting demands for biosimilars and continuous emphasis on cost reduction of drugshave motivated researchers across the globe to widen the horizon of screening in CHO cells based bio-production. Various groups have exploited multiple phenomena in CHO cells for better expression and improved quality of therapeutic protein, for example use of transposons, regulatory elements, engineering of cell lines for site specific integrations or knock-in/knockout models to achieve the desired results. The current study presents the data for evaluation of three mammalian expression platforms available in market having three different approaches for improving productivity. One, the MTX based platforms for gene amplification, GS knock-down based selectionsystem and UCOE based active transcription system. To evaluate the platforms stringently, stable pools of both mAb and non-mAb molecules were accessed. Our results suggested that UCOE based platform have performed exceedingly well in monoclonal antibody (mAb) expression in comparison to the other two platforms. Whereas, for non mAb molecules, UCOE based platform was comparable to other two platforms. On evaluating all the molecules, CHOGS (-) system was found least productive as compared to the other two platforms in almost all cases.